As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts..

Japanese drug maker Daiichi Sankyo Co. and U.S. partner Eli Lilly & Co. sought to reassure investors Friday that a highly anticipated blood thinner remains on track for approval, despite ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...